Generated by AI
Biodexa Pharmaceuticals plc is a clinical-stage biopharmaceutical company focused on developing therapies for diseases with significant unmet medical needs. Its current portfolio centers on oncology, with particular emphasis on treatments intended to address gastrointestinal cancers and other serious conditions. The company applies drug-delivery technologies and pharmaceutical development expertise to advance therapeutic candidates through clinical research and regulatory evaluation. Its activities span preclinical development, clinical-stage programs, intellectual-property management, and collaboration across the biotechnology and healthcare sectors. Biodexa Pharmaceuticals plc operates within the specialized biopharmaceutical market, where companies develop targeted treatments and supporting technologies for complex diseases. Its role is primarily that of a research-driven developer rather than a broad commercial drug manufacturer, with current operations concentrated on advancing innovative therapies toward potential clinical use. The company is incorporated in England and Wales and serves as a publicly traded healthcare asset linked to the biotechnology and medical research industry.
Website1 Caspian Point
Cardiff, CF10 4DQ
United Kingdom
The latest articles about BDRX.
November 9, 2026Biodexa provides R&D Update Phase 3 Serenta trial in FAP is now two-thirds recruitedPreparations advanced for Phase 1 trial of...
Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) stock rose 13.3% to $0.55 during Wednesday's after-market session. Impact BioMedical (AMEX:IBO) stock rose 10.77% to $3.77. The company's market cap stands at
Summary of Oct 27's posts. Generated by AI.
Summary of Oct 14's posts. Generated by AI.
Summary of Oct 15's posts. Generated by AI.
Investors talking about BDRX also mention these. Each card shows that asset’s own numbers for the past 24 hours.